Article Information
PubMed
History
- Published online January 24, 2021.
Article Versions
- Latest version (January 6, 2021 - 09:51).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2021 Joule Inc. or its licensors This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) license, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e. research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/
Author Information
- Peter E. Wu, MD MSc,
- Andrew M. Morris, MD SM
- Department of Medicine (Wu, Morris) Division of Clinical Pharmacology & Toxicology (Wu) and Division of Infectious Diseases (Morris), University of Toronto; Division of General Internal Medicine and Geriatrics (Wu), University Health Network; Division of Infectious Diseases (Morris), Sinai Health and University Health Network, Toronto, Ont.
- Correspondence to: Peter Wu, peter.wu{at}uhn.ca
Statistics from Altmetric.com
In this issue
Article tools
Remdesivir for patients with COVID-19
Jump to section
- Article
- Remdesivir is an antiviral drug with activity against an array of RNA viruses
- Remdesivir has been tested as a treatment for COVID-19 in 2 large clinical trials
- Remdesivir may reduce recovery time but does not reduce mortality
- Remdesvir does not help critically ill patients
- Data for adverse events are limited but include hepatotoxicity and hypersensitivity reactions
- Footnotes
- References
- Responses
- Metrics
Related Articles
Cited By...
- No citing articles found.